Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Nurix Therapeutics Inc NRIX

Healthcare Biotechnology
Nurix Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of small molecules and antibody therapies based on the modulation of cellular protein levels as a treatment approach for cancer, inflammatory conditions and other diseases. It DELigase is an integrated discovery platform, to identify and advance drug... see more

Recent & Breaking News (NDAQ:NRIX)

Nurix Therapeutics Announces $55 Million Registered Direct Offering

GlobeNewswire July 7, 2022

Nurix Therapeutics Reports Fiscal Second Quarter 2022 Financial Results and Provides a Corporate Update

GlobeNewswire July 7, 2022

Nurix Therapeutics Announces Clearance of Investigational New Drug Application For NX-1607 Supporting Plans to Expand Enrollment to U.S. Clinical Sites

GlobeNewswire June 30, 2022

Nurix Therapeutics Will Present Trial in Progress Posters for Two Clinical Programs at the 2022 Annual European Hematology Association (EHA) Congress

GlobeNewswire June 10, 2022

Nurix Therapeutics Will Present Trial in Progress Posters for Three Clinical Programs at the Annual Meeting of the American Society of Clinical Oncology (ASCO)

GlobeNewswire June 3, 2022

Nurix Therapeutics Announces Positive Dose Finding Data in Chronic Lymphocytic Leukemia and Advances NX-2127 to Next Phase of Clinical Development

GlobeNewswire May 26, 2022

Nurix Therapeutics Reports Dosing of First Patient in Phase 1 Clinical Trial of NX-5948, a Selective BTK Degrader, in Development for B-cell Leukemias and Lymphomas

GlobeNewswire May 17, 2022

Nurix Therapeutics Announces Participation in the 2022 RBC Capital Markets Global Healthcare Conference

GlobeNewswire May 11, 2022

Nurix Therapeutics to Host R&D Day on May 26, 2022

GlobeNewswire May 9, 2022

Nurix Therapeutics Presents New Preclinical Data Supporting NX-2127 and DeTIL-0255 Clinical Programs at the American Association for Cancer Research Annual Meeting

GlobeNewswire April 8, 2022

Nurix Therapeutics Reports Fiscal First Quarter 2022 Financial Results and Provides a Corporate Update

GlobeNewswire April 7, 2022

Nurix Therapeutics Doses First Patient in Phase 1 Clinical Trial of DeTIL-0255, a Drug-Enhanced Cell Therapy for the Treatment of Patients with Solid Tumors

GlobeNewswire April 5, 2022

Nurix Therapeutics Announces Participation in the 21st Annual Needham Virtual Healthcare Conference

GlobeNewswire April 4, 2022

Nurix Therapeutics Awarded Innovation Passport for Entry into Innovative Licensing and Access Pathway (ILAP) in the United Kingdom for NX-1607

GlobeNewswire March 29, 2022

Nurix Therapeutics to Participate in Upcoming Investor Conferences

GlobeNewswire March 9, 2022

Nurix Therapeutics to Present Preclinical Data from Its Novel BTK Degrader (NX-2127) and CBL-B Inhibitor (NX-0255) Programs at the American Association for Cancer Research Annual Meeting

GlobeNewswire March 8, 2022

Nurix Therapeutics Announces Participation in the 11th Annual SVB Leerink Global Healthcare Conference

GlobeNewswire February 10, 2022

Nurix Therapeutics Reports Fourth Quarter and Fiscal Year 2021 Financial Results and Provides a Corporate Update

GlobeNewswire January 27, 2022

Nurix Therapeutics Advances Clinical and Preclinical Pipeline and Outlines 2022 Catalysts

GlobeNewswire January 10, 2022

Nurix Therapeutics to Present at 40th Annual J.P. Morgan Healthcare Conference

GlobeNewswire January 3, 2022